• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Efficacy, safety and biomarkers of SG001 for patients with previously treated recurrent or metastatic cervical cancer: an open-label, multicenter, phase Ib trial.

作者信息

Zuo Jing, Duan Wei, Zhao Mingxuan, Chen Zhendong, Lin Jie, Shi Huaqiu, Jiang Ou, Zhang Youzhong, Fang Meiyu, Wang Li, Wang Wei, Huang Yong, Yu Junyan, Zhang Xiaoxue, Pu Weiqing, Hao Deshun, She Fenglin, Yang Xiugao, Chen Ying, Tang Qizhi, Zhang Xiao, Niu Miao, Song Yan'e, Wu Lingying

机构信息

Department of Gynecology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P. R. China.

Department of Gynecology and Oncology, Beijing Obstetrics and Gynecology Hospital, Beijing, P. R. China.

出版信息

Cancer Commun (Lond). 2024 Sep;44(9):1042-1046. doi: 10.1002/cac2.12578. Epub 2024 Jul 23.

DOI:10.1002/cac2.12578
PMID:39044367
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11492360/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6d98/11492360/f038d30d7a33/CAC2-44-1042-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6d98/11492360/f038d30d7a33/CAC2-44-1042-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6d98/11492360/f038d30d7a33/CAC2-44-1042-g001.jpg

相似文献

1
Efficacy, safety and biomarkers of SG001 for patients with previously treated recurrent or metastatic cervical cancer: an open-label, multicenter, phase Ib trial.SG001用于既往接受过治疗的复发性或转移性宫颈癌患者的疗效、安全性及生物标志物：一项开放标签、多中心、Ib期试验
Cancer Commun (Lond). 2024 Sep;44(9):1042-1046. doi: 10.1002/cac2.12578. Epub 2024 Jul 23.
2
Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study.替妥珠单抗Vedotin 在既往治疗的复发或转移性宫颈癌中的疗效和安全性（innovaTV 204/GOG-3023/ENGOT-cx6）：一项多中心、开放标签、单臂、2 期研究。
Lancet Oncol. 2021 May;22(5):609-619. doi: 10.1016/S1470-2045(21)00056-5. Epub 2021 Apr 9.
3
Efficacy and safety of zimberelimab (GLS-010) monotherapy in patients with recurrent or metastatic cervical cancer: a multicenter, single-arm, phase II study.zimberelimab（GLS-010）单药治疗复发性或转移性宫颈癌患者的疗效和安全性：一项多中心、单臂、II 期研究。
Int J Gynecol Cancer. 2023 Dec 4;33(12):1861-1868. doi: 10.1136/ijgc-2023-004705.
4
Safety and Efficacy of the mTOR Inhibitor, Vistusertib, Combined With Anastrozole in Patients With Hormone Receptor-Positive Recurrent or Metastatic Endometrial Cancer: The VICTORIA Multicenter, Open-label, Phase 1/2 Randomized Clinical Trial.mTOR抑制剂维司他昔联合阿那曲唑治疗激素受体阳性复发或转移性子宫内膜癌患者的安全性和有效性：维多利亚多中心、开放标签、1/2期随机临床试验
JAMA Oncol. 2022 Jul 1;8(7):1001-1009. doi: 10.1001/jamaoncol.2022.1047.
5
Phase Ib study of the mitochondrial inhibitor ME-344 plus topotecan in patients with previously treated, locally advanced or metastatic small cell lung, ovarian and cervical cancers.既往治疗的局部晚期或转移性小细胞肺癌、卵巢癌和宫颈癌患者中，线粒体抑制剂 ME-344 联合拓扑替康的 Ib 期研究。
Invest New Drugs. 2017 Oct;35(5):627-633. doi: 10.1007/s10637-017-0444-1. Epub 2017 Mar 10.
6
Efficacy and safety of sintilimab plus albumin-bound-paclitaxel in recurrent or metastatic cervical cancer: a multicenter, open-label, single-arm, phase II trial.信迪利单抗联合白蛋白结合型紫杉醇治疗复发或转移性宫颈癌的疗效和安全性：一项多中心、开放标签、单臂、II期试验。
EClinicalMedicine. 2023 Oct 24;65:102274. doi: 10.1016/j.eclinm.2023.102274. eCollection 2023 Nov.
7
Mitochondrially targeted tamoxifen in patients with metastatic solid tumours: an open-label, phase I/Ib single-centre trial.线粒体靶向他莫昔芬治疗转移性实体瘤患者：一项开放标签的I/Ib期单中心试验。
EClinicalMedicine. 2023 Feb 23;57:101873. doi: 10.1016/j.eclinm.2023.101873. eCollection 2023 Mar.
8
Nivolumab with or without ipilimumab in patients with recurrent or metastatic cervical cancer (CheckMate 358): a phase 1-2, open-label, multicohort trial.纳武利尤单抗联合或不联合伊匹木单抗治疗复发性或转移性宫颈癌患者（CheckMate 358）：一项1/2期、开放标签、多队列试验
Lancet Oncol. 2024 May;25(5):588-602. doi: 10.1016/S1470-2045(24)00088-3. Epub 2024 Apr 9.
9
Phase I Trial of First-line Bintrafusp Alfa in Patients with Locally Advanced or Persistent/Recurrent/Metastatic Cervical Cancer.Bintrafusp Alfa 一线治疗局部晚期或持续性/复发性/转移性宫颈癌的 I 期临床试验。
Clin Cancer Res. 2024 Mar 1;30(5):975-983. doi: 10.1158/1078-0432.CCR-23-1829.
10
Camrelizumab (SHR-1210) with carboplatin and albumin-binding paclitaxel in patients with metastatic or recurrent cervical cancer: An open-label, phase 2 trial.卡瑞利珠单抗（SHR-1210）联合卡铂和白蛋白紫杉醇治疗转移性或复发性宫颈癌患者的开放标签、Ⅱ期临床试验。
J Cancer Res Ther. 2022 Apr;18(2):482-487. doi: 10.4103/jcrt.jcrt_1851_21.

引用本文的文献

1
Enlonstobart: First Approval.恩洛司托巴特：首次获批。
Drugs. 2024 Dec;84(12):1659-1663. doi: 10.1007/s40265-024-02119-z. Epub 2024 Nov 19.

本文引用的文献

1
Efficacy and Prognostic Factors for Response to PD-1 Inhibitors in Advanced Cervical Carcinoma: A Retrospective Study.晚期宫颈癌中PD-1抑制剂治疗反应的疗效及预后因素：一项回顾性研究
Drug Des Devel Ther. 2022 Mar 29;16:887-897. doi: 10.2147/DDDT.S358302. eCollection 2022.
2
Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer.派姆单抗治疗持续性、复发性或转移性宫颈癌。
N Engl J Med. 2021 Nov 11;385(20):1856-1867. doi: 10.1056/NEJMoa2112435. Epub 2021 Sep 18.
3
Phase II study of the safety and efficacy of the anti-PD-1 antibody balstilimab in patients with recurrent and/or metastatic cervical cancer.
抗 PD-1 抗体巴替利单抗治疗复发性和/或转移性宫颈癌患者的安全性和有效性的 II 期研究。
Gynecol Oncol. 2021 Nov;163(2):274-280. doi: 10.1016/j.ygyno.2021.08.018. Epub 2021 Aug 25.
4
Genomic profiling of advanced cervical cancer to predict response to programmed death-1 inhibitor combination therapy: a secondary analysis of the CLAP trial.晚期宫颈癌的基因组分析预测程序性死亡受体-1 抑制剂联合治疗的反应：CLAP 试验的二次分析。
J Immunother Cancer. 2021 May;9(5). doi: 10.1136/jitc-2020-002223.
5
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.《全球癌症统计数据 2020：全球 185 个国家和地区 36 种癌症的发病率和死亡率估计》。
CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4.
6
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study.帕博利珠单抗治疗的晚期实体瘤患者肿瘤突变负荷与结局的相关性：多队列、开放标签、Ⅱ期 KEYNOTE-158 研究的前瞻性生物标志物分析。
Lancet Oncol. 2020 Oct;21(10):1353-1365. doi: 10.1016/S1470-2045(20)30445-9. Epub 2020 Sep 10.
7
Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 Trial.尼伏鲁单抗单药治疗复发性或转移性宫颈癌、阴道癌或外阴癌的安全性和疗效：来自 I/II 期 CheckMate 358 试验的结果。
J Clin Oncol. 2019 Nov 1;37(31):2825-2834. doi: 10.1200/JCO.19.00739. Epub 2019 Sep 5.
8
Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study.帕博利珠单抗治疗既往治疗的晚期宫颈癌的疗效和安全性：来自 II 期 KEYNOTE-158 研究的结果。
J Clin Oncol. 2019 Jun 10;37(17):1470-1478. doi: 10.1200/JCO.18.01265. Epub 2019 Apr 3.
9
Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1-Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial.帕博利珠单抗治疗晚期程序性死亡配体 1 阳性宫颈癌的安全性和有效性：来自 Ib 期 KEYNOTE-028 试验的结果。
J Clin Oncol. 2017 Dec 20;35(36):4035-4041. doi: 10.1200/JCO.2017.74.5471. Epub 2017 Nov 2.